Royalty Pharma plc has completed the acquisition of its external manager, RP Management, LLC, marking a significant milestone for the company. This transaction, which received 99.9% shareholder approval, transitions Royalty Pharma from an external management model to an internalized structure. All employees of RP Management have now become employees of Royalty Pharma. This move is expected to enhance shareholder value through improved governance and reduced costs, while better positioning the company to support innovation in the life sciences industry. Royalty Pharma will update its full-year 2025 guidance to reflect this change when it reports its second quarter 2025 financial results.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。